Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

58
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
58
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

32
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
32
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

587
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
587
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

278
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
278
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

77
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
77
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

121
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using human genetic variation to estimate the effect of lipoprotein(a) lowering on pregnancy outcomes.

medRxiv : the preprint server for health sciences·2026
Same author

The genetic architecture of postoperative delirium after major surgery and its relationship with nonpostoperative neurocognitive conditions: A genome-wide association study.

PLoS medicine·2026
Same author

<i>CanDrivR-CS</i>: a cancer-specific machine learning framework for distinguishing recurrent and rare variants.

Bioinformatics advances·2026
Same author

Distinct pathway-based effects of blood pressure and body mass index on cardiovascular traits: comparison of novel Mendelian randomization approaches.

Genome medicine·2025
Same author

Immunological drivers and potential novel drug targets for major psychiatric, neurodevelopmental, and neurodegenerative conditions.

Molecular psychiatry·2025
Same author

Transcriptome-wide Mendelian randomization during CD4<sup>+</sup> T cell activation reveals immune-related drug targets for cardiometabolic diseases.

Nature communications·2024
Same journal

OmicsTransformer: Self-Supervised Masked Consistency and Uncertainty-Aware Fusion for Robust Multi-Omics Prediction.

Bioinformatics (Oxford, England)·2026
Same journal

Computational Tool Choice Impacts CRISPR Spacer-Proto spacer Detection.

Bioinformatics (Oxford, England)·2026
Same journal

ARISE: RNA-Anchored Shared-Edge Topology and Hierarchical Fusion for Spatial Multi-Omics Integration.

Bioinformatics (Oxford, England)·2026
Same journal

Interactive exploration of biobank-scale ancestral recombination graphs with Lorax.

Bioinformatics (Oxford, England)·2026
Same journal

PepMCP: A Graph-Based Membrane Contact Probability Predictor for Membrane-Lytic Antimicrobial Peptides.

Bioinformatics (Oxford, England)·2026
Same journal

ARGscape: A modular, interactive tool for manipulation of spatiotemporal ancestral recombination graphs.

Bioinformatics (Oxford, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Fast polypharmacy side effect prediction using tensor factorization.

Oliver Lloyd1, Yi Liu1, Tom R Gaunt1

  • 1MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, BS8 2BN, United Kingdom.

Bioinformatics (Oxford, England)
|November 25, 2024
PubMed
Summary
This summary is machine-generated.

Optimized tensor factorization models accurately predict drug combination adverse reactions. The SimplE model achieves state-of-the-art results efficiently, offering a faster alternative for polypharmacy side effect prediction.

More Related Videos

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

1.7K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.4K

Related Experiment Videos

Last Updated: Jun 6, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
06:50

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

1.7K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.4K

Area of Science:

  • Computational chemistry
  • Pharmacology
  • Bioinformatics

Background:

  • Adverse drug reactions from combinations are a growing concern in medicine.
  • Laboratory methods are insufficient for predicting these combinatorial effects.
  • Computational approaches, including tensor factorization (TF), have shown potential but require optimization.

Purpose of the Study:

  • To investigate the efficacy of optimized tensor factorization models for polypharmacy side effect prediction.
  • To evaluate the performance and efficiency of TF models compared to existing methods.
  • To determine the optimal incorporation of monopharmacy data within TF models.

Main Methods:

  • Utilized tensor factorization (TF) models, specifically the SimplE model, for predicting polypharmacy side effects.
  • Incorporated monopharmacy data as self-looping edges in a graph-based approach.
  • Trained models using Python 3.8.12 with PyTorch 1.7.1 on NVIDIA GPUs.

Main Results:

  • The SimplE TF model achieved state-of-the-art performance, with AUC ROC of 0.978, AUC PR of 0.971, and AP@50 of 1.000 across 963 side effects.
  • The model reached 98.3% of its peak performance within two training epochs (approx. 4 minutes), demonstrating significant speed advantages.
  • Integrating monopharmacy data as self-looping edges yielded slightly better results than using it for embedding initialization.

Conclusions:

  • Optimized tensor factorization models, like SimplE, are highly effective for predicting polypharmacy side effects.
  • These models offer a computationally efficient and accurate solution compared to existing methods.
  • The study highlights the potential of TF for advancing drug safety and personalized medicine.